Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 8, 2014 - Issue 1
Submit an article Journal homepage
628
Views
13
CrossRef citations to date
0
Altmetric
Reviews

Hepatocellular carcinoma and cholangiocarcinoma: an update

Cemal YaziciDivision of Hepatology and HPB Surgery, Carolinas Medical Center, Charlotte, NC, USA
,
David J NiemeyerDivision of Hepatology and HPB Surgery, Carolinas Medical Center, Charlotte, NC, USA
,
David A IannittiDivision of Hepatology and HPB Surgery, Carolinas Medical Center, Charlotte, NC, USA
&
Mark W RussoDivision of Hepatology and HPB Surgery, Carolinas Medical Center, Charlotte, NC, USACorrespondence[email protected]
Pages 63-82 | Published online: 05 Dec 2013

References

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 (2011).
  • Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27(9), 1485–1491 (2009).
  • Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology 48(1), 137–145 (2008).
  • El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol. Res. 37(Suppl. 2), S88–94 (2007).
  • El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med. 139(10), 817–823 (2003).
  • Hamed O, Kimchi ET, Sehmbey M, Gusani NJ, Kaifi JT, Staveley-O'Carroll K. Impact of genetic targets on cancer therapy: hepatocellular cancer. Adv. Exp. Med. Biol. 779, 67–90 (2013).
  • Suzuki Y, Imai K, Takai K et al. Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test. J. Cancer Res. Clin. Oncol. 139(5), 845–852 (2013).
  • Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J. Hepatol. 52(2), 252–257 (2010).
  • Ozen C, Yildiz G, Dagcan AT et al. Genetics and epigenetics of liver cancer. N. Biotechnol. 30(4), 381–384 (2013).
  • Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359(19), 1995–2004 (2008).
  • Davies P. New kids on the block. BMJ 341, c4421 (2010).
  • Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 57(2), 840–847 (2013).
  • Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 53(3), 1020–1022 (2011).
  • Lok AS, Seeff LB, Morgan TR et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136(1), 138–148 (2009).
  • Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur. J. Gastroenterol. Hepatol. 12(8), 941–948 (2000).
  • World Health Organization, International Agency for Research on Cancer. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Press, Lyon, France, 82, 1–556 (2002).
  • Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51(5), 1820–1832 (2010).
  • White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 10(12), 1342–1359 (2012) e2.
  • Yeoman AD, Al-Chalabi T, Karani JB et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 48(3), 863–870 (2008).
  • Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am. J. Gastroenterol. 96(4), 1160–1163 (2001).
  • Fevery J, Henckaerts L, Van Oirbeek R et al. Malignancies and mortality in 200 patients with primary sclerosing cholangitis: a long-term single-centre study. Liver Int. 32(2), 214–222 (2012).
  • Elmberg M, Hultcrantz R, Ekbom A et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 125(6), 1733–1741 (2003).
  • Chang MH, You SL, Chen CJ et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst. 101(19), 1348–1355 (2009).
  • Turner PC, Sylla A, Gong YY et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study. Lancet 365(9475), 1950–1956 (2005).
  • Chen JG, Parkin DM, Chen QG et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J. Med. screen. 10(4), 204–209 (2003).
  • Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 130(7), 417–422 (2004).
  • EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908–943 (2012).
  • Trevisani F, D'Intino PE, Morselli-Labate AM et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 34(4), 570–575 (2001).
  • Singal A, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment. Pharmacol. Ther. 30(1), 37–47 (2009).
  • Trinchet JC, Chaffaut C, Bourcier V et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 54(6), 1987–1997 (2011).
  • Wang JH, Chang KC, Kee KM et al. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am. J. Gastroenterol. 108(3), 416–424 (2013).
  • Sterling RK, Jeffers L, Gordon F et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 7(1), 104–113 (2009).
  • Adachi Y, Tsuchihashi J, Shiraishi N, Yasuda K, Etoh T, Kitano S. AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology 65(2), 95–101 (2003).
  • Gur T, Demir H, Kotan MC. Tumor markers and biochemical parameters in colon cancer patients before and after chemotherapy. Asian Pac. J. Cancer Prev. 12(11), 3147–3150 (2011).
  • Okuda H, Shiratori K, Yamamoto M, Takasaki K, Nakano M. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma. J. Gastroenterol. Hepatol. 21(5), 869–873 (2006).
  • Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA. Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266(2), 376–382 (2013).
  • Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 11(3), 281–289 (2005).
  • Yu JS, Lee JH, Chung JJ, Kim JH, Kim KW. Small hypervascular hepatocellular carcinoma: limited value of portal and delayed phases on dynamic magnetic resonance imaging. Acta Radiol. 49(7), 735–743 (2008).
  • Vilana R, Forner A, Bianchi L et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51(6), 2020–2029 (2010).
  • Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2), 658–664 (2009).
  • Poon D, Anderson BO, Chen LT et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 10(11), 1111–1118 (2009).
  • Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19(3), 329–338 (1999).
  • Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56(4), 918–928 (1985).
  • Ikai I, Takayasu K, Omata M et al. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J. Gastroenterol. 41(9), 884–892 (2006).
  • Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37(2), 429–442 (2003).
  • Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319), 1734–1739 (2002).
  • Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5), 1164–1171 (2002).
  • Castells A, Bruix J, Ayuso C et al. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J. Hepatol. 22(4), 410–415 (1995).
  • Russo gMW Hepatocellular Carcinoma and Cholangiocarcinoma. In: Common Liver Diseases and Transplantation. An Algorithmic Approach to Work-up and Management. Brown RJ (Ed.). SLACK incorporated, Thorofare, NJ, USA (2013).
  • Ashoori N, Bamberg F, Paprottka P et al. Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation. Digestion 86(4), 338–348 (2012).
  • Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl. 11(7), 767–775 (2005).
  • Yao FY, Hirose R, LaBerge JM et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 11(12), 1505–1514 (2005).
  • Patel SS, Arrington AK, McKenzie S et al. Milan Criteria and UCSF Criteria: a Preliminary Comparative Study of Liver Transplantation Outcomes in the United States. Int. J. Hepatol. 2012, 253517 (2012).
  • Salem R, Lewandowski RJ, Mulcahy MF et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1), 52–64 (2010).
  • Moreno-Luna LE, Yang JD, Sanchez W et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc. Interv. Radiol. 36(3), 714–723 (2013).
  • Sangro B, Carpanese L, Cianni R et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54(3), 868–878 (2011).
  • Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008).
  • Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25–34 (2009).
  • Zhao Y, Wang WJ, Guan S et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann. Oncol. 24(7), 1786–1792 (2013).
  • Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47(1), 82–89 (2008).
  • Swan RZ, Sindram D, Martinie JB, Iannitti DA. Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes. J. Gastrointest. Surg. 17(4), 719–729 (2013).
  • Bertot LC, Sato M, Tateishi R, Yoshida H, Koike K. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. Eur. Radiol. 21(12), 2584–2596 (2011).
  • van Vledder MG, Pawlik TM, Munireddy S, Hamper U, de Jong MC, Choti MA. Factors determining the sensitivity of intraoperative ultrasonography in detecting colorectal liver metastases in the modern era. Ann. Surg. Oncol. 17(10), 2756–2763 (2010).
  • Peng ZW, Zhang YJ, Chen MS et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J. Clin. Oncol. 31(4), 426–432 (2013).
  • Liu Y, Zheng Y, Li S, Li B, Zhang Y, Yuan Y. Percutaneous microwave ablation of larger hepatocellular carcinoma. Clin. Radiol. 68(1), 21–26 (2013).
  • Guglielmi A, Ruzzenente A, Valdegamberi A et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J. Gastrointest. Surg. 12(1), 192–198 (2008).
  • Duffy JP, Hiatt JR, Busuttil RW. Surgical resection of hepatocellular carcinoma. Cancer J. 14(2), 100–110 (2008).
  • Chan AC, Chan SC, Chok KS et al. Treatment strategy for recurrent hepatocellular carcinoma: Salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl. 19(4), 411–419 (2013).
  • Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334(11), 693–699 (1996).
  • Freeman RB, Mithoefer A, Ruthazer R et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database. Liver Transpl. 12(10), 1504–1511 (2006).
  • Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10(1), 35–43 (2009).
  • Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin. Liver Dis. 24(2), 115–125 (2004).
  • Hong JC, Jones CM, Duffy JP et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch. Surg. 146(6), 683–689 (2011).
  • Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 37(5), 961–969 (2003).
  • Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310(5756), 1966–1970 (2005).
  • Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim. Biophys. Acta. 1755(2), 135–150 (2005).
  • Aishima S, Mano Y, Tanaka Y et al. Different roles of inducible nitric oxide synthase and cyclooxygenase-2 in carcinogenesis and metastasis of intrahepatic cholangiocarcinoma. Hum. Pathol. 44(6), 1031–1037 (2013).
  • Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J. Hepatol. 57(1), 69–76 (2012).
  • Jeong CY, Hah YS, Cho BI et al. Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma. Oncol. Rep. 28(4), 1283–1292 (2012).
  • Andersen JB, Spee B, Blechacz BR et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142(4), 1021–1031 (2012) e15.
  • Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 128(6), 1655–1667 (2005).
  • Bergquist A, Ekbom A, Olsson R et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J. Hepatol. 36(3), 321–327 (2002).
  • Bouvard V, Baan R, Straif K et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 10(4), 321–322 (2009).
  • Shin HR, Oh JK, Masuyer E et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 101(3), 579–585 (2010).
  • Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. 95(1), 204–207 (2000).
  • Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19–9 in acute cholangitis. Dig. Dis. Sci. 33(10), 1223–1225 (1988).
  • Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant. Proc. 41(10), 4023–4035 (2009).
  • Ritts RE, Pitt HA. CA 19–9 in pancreatic cancer. Surg. Oncol. Clin. N. Am. 7(1), 93–101 (1998).
  • Vestergaard EM, Hein HO, Meyer H et al. Reference values and biological variation for tumor marker CA 19–9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin. chem. 45(1), 54–61 (1999).
  • Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 48(4), 1106–1117 (2008).
  • Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J. Gastroenterol. 15(34), 4240–4262 (2009).
  • Petrowsky H, Wildbrett P, Husarik DB et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J. Hepatol. 45(1), 43–50 (2006).
  • Kim JY, Kim MH, Lee TY et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am. J. Gastroenterol. 103(5), 1145–1151 (2008).
  • Baron TH, Harewood GC, Rumalla A et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin. Gastroenterol. Hepatol. 2(3), 214–219 (2004).
  • Fritcher EG, Kipp BR, Halling KC et al. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology 136(7), 2180–2186 (2009).
  • Rimola J, Forner A, Reig M et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50(3), 791–798 (2009).
  • Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 8(9), 512–522 (2011).
  • Dingle BH, Rumble RB, Brouwers MC. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can. J. Gastroenterol. 19(12), 711–716 (2005).
  • Paule B, Herelle MO, Rage E et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72(1–2), 105–110 (2007).
  • Gruenberger B, Schueller J, Heubrandtner U et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 11(12), 1142–1148 (2010).
  • Saito H, Takada T, Miyazaki M et al. Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas. J. Hepatobiliary Pancreat. Surg. 15(1), 63–68 (2008).
  • Brunner TB, Eccles CL. Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther. Onkol. 186(12), 672–680 (2010).
  • Todoroki T, Ohara K, Kawamoto T et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 46(3), 581–587 (2000).
  • Gwak HK, Kim WC, Kim HJ, Park JH. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 78(1), 194–198 (2010).
  • Nelson JW, Ghafoori AP, Willett CG et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 73(1), 148–153 (2009).
  • Darwish Murad S, Heimbach JK, Gores GJ, Rosen CB, Benson JT, Kim WR. Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. Liver Transpl. 19(5), 521–528 (2013).
  • Nakeeb A, Pitt HA. Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HPB (Oxford). 7(4), 278–282 (2005).
  • Panjala C, Nguyen JH, Al-Hajjaj AN et al. Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma. Liver Transpl. 18(5), 594–601 (2012).
  • Nakeeb A, Pitt HA, Sohn TA et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. 224(4), 463–473; discussion 73–75 (1996).
  • Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg. Gynecol. Obstet. 140(2), 170–178 (1975).
  • Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Sueda T. Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis. World J Surg. 31(2), 337–342; discussion 43–44 (2007).
  • Fu Y, Yang W, Wu W, Yan K, Xing BC, Chen MH. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J. Vasc. Interv. Radiol. 23(5), 642–649 (2012).
  • Tsao JI, Nimura Y, Kamiya J et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg. 232(2), 166–174 (2000).
  • Fan WJ, Wu PH, Zhang L et al. Radiofrequency ablation as a treatment for hilar cholangiocarcinoma. World J. Gastroenterol. 14(28), 4540–4545 (2008).
  • Heimbach JK, Gores GJ, Haddock MG et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 82(12), 1703–1707 (2006).
  • Hong JC, Petrowsky H, Kaldas FM et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J. Am. Coll. Surg. 212(4), 514–520; discussion 20–21 (2011).
  • Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 344(8938), 1655–1660 (1994).
  • Speer AG, Cotton PB, Russell RC et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 2(8550), 57–62 (1987).
  • Pinol V, Castells A, Bordas JM et al. Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary obstruction: randomized clinical trial. Radiology 225(1), 27–34 (2002).
  • Park do H, Song TJ, Eum J et al. EUS-guided hepaticogastrostomy with a fully covered metal stent as the biliary diversion technique for an occluded biliary metal stent after a failed ERCP (with videos). Gastrointest. Endosc. 71(2), 413–419 (2010).
  • Park do H, Jang JW, Lee SS, Seo DW, Lee SK, Kim MH. EUS-guided biliary drainage with transluminal stenting after failed ERCP: predictors of adverse events and long-term results. Gastrointest. Endosc. 74(6), 1276–1284 (2011).
  • De Palma GD, Galloro G, Siciliano S, Iovino P, Catanzano C. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest. Endosc. 53(6), 547–553 (2001).
  • Hwang JC, Kim JH, Lim SG, Kim SS, Yoo BM, Cho SW. Y-shaped endoscopic bilateral metal stent placement for malignant hilar biliary obstruction: prospective long-term study. Scand. J. Gastroenterol. 46(3), 326–332 (2011).
  • Liberato MJ, Canena JM. Endoscopic stenting for hilar cholangiocarcinoma: efficacy of unilateral and bilateral placement of plastic and metal stents in a retrospective review of 480 patients. BMC Gastroenterol. 12, 103 (2012).
  • Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat. Rev. Cancer 3(5), 380–387 (2003).
  • Ortner ME, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125(5), 1355–1363 (2003).
  • Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am. J. Gastroenterol. 100(11), 2426–2430 (2005).
  • Valle JW, Wasan H, Johnson P et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised Phase II study – the UK ABC-01 Study. B. J. Cancer 101(4), 621–627 (2009).
  • Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362(14), 1273–1281 (2010).
  • Okusaka T, Nakachi K, Fukutomi A et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. B. J. Cancer 103(4), 469–474 (2010).
  • Sotiropoulos GC, Kaiser GM, Lang H et al. Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience. Transplant Proc. 40(9), 3194–3195 (2008).
  • Becker NS, Rodriguez JA, Barshes NR, O'Mahony CA, Goss JA, Aloia TA. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J. Gastrointest. Surg. 12(1), 117–122 (2008).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.